Ann: G-BA Approval received for OncoSil Device, page-23

Thanks for sharing that info! I think it’s worth highlighting that this reimbursement isn’t just about covering the trial costs. Under the NUB pricing structure, OncoSil will actually be reimbursed at the full commercial sale price for each participant, based on rates negotiated individually with each hospital. This is a big step beyond standard cost coverage and sets the stage for significant revenue.In the investor webinar Nigel gave in August to the Capital Network, he referred to the G-BA approval as an “absolute game changer,” adding that “Break Even would happen very, very quickly.” You can check out this segment around the 34-minute mark here https://youtu.be/77w-cpJJ_9M?si=GyXRQmb0O0mOupp9
For additional context, see slides 9 and 10 of the ASX Investor Presentation from March, which outline the framework for this week’s approval https://clients3.weblink.com.au/**promotion blocked**/announcement.aspx?articleID=464112